An open-label, randomized, cross-over bioequivalence study of lafutidine 10 mg under fasting condition

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 1, Issue 5

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

527

HTML

4197

Figures (1-2)

468

Tables (1-3)

308

Sum=5500

Oct 6, 2010 (publication date) through Sep 1, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastrointest Pharmacol Ther. Oct 6, 2010; 1(5): 112-118
Published online Oct 6, 2010. doi: 10.4292/wjgpt.v1.i5.112

Table 2 Ratio (Test/Reference), 90% confidence interval and intra-subject variation following the administration of 10 mg lafutidine tablets

Parameters	Ratio (Test/Reference, %)	90% Confidence interval (Log transformed data)	Intrasubject variability (Log transformed data, %)
C_max	106.69	101.86-111.74	9.36
AUC_(0-t)	107.90	102.25-113.86	10.88
AUC_(0-∞)	108.14	102.56-114.03	10.73

AUC: Area under the curve.

Citation: Dewan B, Chimata R. An open-label, randomized, cross-over bioequivalence study of lafutidine 10 mg under fasting condition. World J Gastrointest Pharmacol Ther 2010; 1(5): 112-118
URL: https://www.wjgnet.com/2150-5349/full/v1/i5/112.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v1.i5.112